Actually, the news today regarding the assay screening test is extremely important to improving the success rate of current clinical trials and future treatment for any medical condition, including cancer where CC5R density is relevant to treatment efficacy. Selecting trial participants moves to another level and ultimately doctors will know in advance, whether or not a drug, such as Leronlimab will be an effective treatment addition for a particular patient. To say the least, this is a terrific discovery.